Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability (Q34548876)

3 August 2017

1 reference

title

Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability (English)

1 reference

3 August 2017

1 reference

M Lynn Crismon

1 reference

3 August 2017

Anthony DeLeon

1 reference

3 August 2017

Nick C Patel

series ordinal

1 reference

3 August 2017

publication date

1 May 2004

1 reference

3 August 2017

published in

Clinical Therapeutics

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

649-666

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

3 August 2017

1 reference

7 January 2021

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Partial dopamine agonists in the treatment of psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Radioreceptor binding profile of the atypical antipsychotic olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

"Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

The neurobiology and control of anxious states

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

A double-blind pilot study of risperidone in the treatment of conduct disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Mechanism of new antipsychotic medications: occupancy is not just antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990066-5

7 January 2021

10.1016/S0149-2918(04)90066-5

Identifiers

DOI

1 reference

3 August 2017

1 reference